Post by Lonza

Asia-Pacific has rapidly emerged as a global innovation hub for next-generation modalities. South Korea, Japan, Singapore, and China are seeing strong ADC-related investment, partnerships, and infrastructure buildout. As the region becomes more integrated into the global pharmaceutical supply chain, companies are increasingly turning to strategic CDMO partnerships to accelerate timelines, manage risk, and scale advanced bioconjugates. At the World ADC Summit South Korea 2026, Marcel Scheepstra, Director of Organic Chemistry in Bioconjugates Research, shared insights on the trends shaping ADC research and development across APAC and spoke with BioSpectrum Asia about how Lonza’s ADC platform technologies are supporting the region’s pharma and biotech players advance innovations from concept through commercialization. Read Marcel’s insights here: https://ow.ly/U0Yl50Zlrvr #WorldADCAsia2026 #Lonza #CDMO #ADC #Bioconjugation #CancerTherapy